Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 22, 2026

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**") announces that, at the 2026 first extraordinary general meeting of the Company (the "**EGM**") held at 2:00 p.m. (Hong Kong time) on Tuesday, September 22, 2026 at Ballroom, 2/F, L'Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, the proposed resolutions set out in the notice of the EGM were passed by way of poll.

References are made to the notice of the EGM and the circular of the Company both dated August 31, 2026 (the "**Circular**") in relation to (i) the proposed increase to the limit for purchase of wealth management products and cash flow management using internal funds; and (ii) the proposed adjustment to the credit line and providing guarantee limit to the banks for 2026. Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The executive directors of the Company: Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Wang Jianyi; and the independent non-executive directors of the Company: Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong, attended the EGM, in person or by electronic means.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of Shares in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The Company did not hold any treasury Shares or repurchased Shares pending cancellation. No Shareholder was required to abstain from voting on the resolutions under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). There was no Share entitling the holder to attend the meeting and abstain from voting in favor of the resolutions as set out in Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the PRC and the Company's article of association.

The total number of Shares entitling the holders to attend and vote on the resolutions at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 992,838,085 Shares (including 981,839,573 A Shares and 10,998,512 H Shares), representing approximately 67.66% of the total number of Shares.

The poll results in respect of the resolutions at the EGM are set out below:

NO.	ORDINARY RESOLUTION	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	The resolution regarding the Company's increase to the limit for purchase of wealth management products and cash flow management using internal funds.	973,119,971 98.0140%	19,693,914 1.9836%	24,200 0.0024%
NO.	SPECIAL RESOLUTION	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
2.	The resolution regarding the Company's adjustment to the credit line and providing guarantee to the banks for 2026.	991,819,294 99.8974%	969,991 0.0977%	48,800 0.0049%

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the resolution numbered 1, such resolution was duly passed as an ordinary resolution.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the resolution numbered 2, such resolution was duly passed as a special resolution.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
September 22, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Wang Jianyi; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.